Retargeting adenoviruses for therapeutic applications and vaccines

FEBS Lett. 2020 Jun;594(12):1918-1946. doi: 10.1002/1873-3468.13731. Epub 2020 Feb 3.

Abstract

Adenoviruses (Ads) are robust vectors for therapeutic applications and vaccines, but their use can be limited by differences in their in vitro and in vivo pharmacologies. This review emphasizes that there is not just one Ad, but a whole virome of diverse viruses that can be used as therapeutics. It discusses that true vector targeting involves not only retargeting viruses, but importantly also detargeting the viruses from off-target cells.

Keywords: Ad serotypes; detargeting; gain of function; liver; retargeting; sequestration; serotypes.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Adenoviridae / classification
  • Adenoviridae / genetics*
  • Animals
  • Biotinylation
  • Capsid Proteins / genetics
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / genetics*
  • Genetic Vectors / pharmacokinetics*
  • Humans
  • Injections, Intravenous
  • Ligands
  • Liver / drug effects
  • Microorganisms, Genetically-Modified
  • Oncolytic Viruses / genetics
  • Peptide Library
  • Tissue Distribution
  • Vaccines / administration & dosage
  • Vaccines / genetics

Substances

  • Capsid Proteins
  • Ligands
  • Peptide Library
  • Vaccines